FDA to review BLA for Merck’s bezlotoxumab
27 January 2016 | By Victoria White
Bezlotoxumab is designed to neutralize C. difficile toxin B, a toxin that can damage the gut wall and cause inflammation, leading to C. difficile-associated diarrhoea...
List view / Grid view
News
Cosentyx to achieve blockbuster status
27 January 2016 | By Victoria White
Alexandra Annis states that Cosentyx's latest approval will bring exciting new treatment options to US patients dissatisfied with current therapies...
Presentation videos from the World’s 1st International Pharmaceutical seminar on Transmission Raman Spectroscopy available online
27 January 2016 | By Colbalt Light System
Videos of the presentations from the world’s 1st TRS seminar for quantitative pharmaceutical analysis can be viewed on demand...
NICE recommends five new therapies
27 January 2016 | By Victoria White
NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS...
Afatinib demonstrates superior PFS to gefitinib in NSCLC trial
27 January 2016 | By Victoria White
Results from the LUX-Lung 7 trial demonstrated superiority in progression-free survival and time to treatment failure with Boehringer Ingelheim’s Giotrif/Gilotrif (afatinib) versus Iressa (gefitinib)...
NICE recommends 7 DMARDs for severe rheumatoid arthritis
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
Epilepsy drug shows promise in protecting nerves from damage in MS
26 January 2016 | By Victoria White
Researchers from UCL found the anti-convulsant drug phenytoin protected neural tissue in patients with optic neuritis - often the first symptom of MS...
FDA accepts filing of cardiovascular outcomes for Jardiance
26 January 2016 | By Victoria White
The FDA has accepted a sNDA for Jardiance (empagliflozin) based on cardiovascular risk reduction data from the EMPA-REG OUTCOME trial...
FDA accepts BLA for Amgen’s Humira biosimilar, ABP 501
26 January 2016 | By Victoria White
Humira (adalimumab) is an anti-TNF-α monoclonal antibody which is approved in many regions for the treatment of several inflammatory diseases...
Keytruda and AFM13 to be investigated in Hodgkin lymphoma
25 January 2016 | By Victoria White
The purpose of the study is to establish a dosing regimen for this combination therapy and assess its safety and efficacy...
Empower your research with Tecan’s Spark® 20M multimode reader
25 January 2016 | By Tecan
Tecan has launched the Spark® 20M multimode microplate reader, offering tailor-made solutions to suit virtually any drug discovery or advanced life science research application...
Ixchelsis announces positive Phase 2a results for IX-01
25 January 2016 | By Victoria White
IX-01 is an oral oxytocin receptor antagonist being developed for the treatment of premature ejaculation...
Shire resubmits NDA for lifitegrast to the FDA
25 January 2016 | By Victoria White
Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA in October last year...
Broad Institute Genomic Services offers genomic insight into Ninlaro
25 January 2016 | By Victoria White
Ninlaro (ixazomib) was recently approved by the FDA, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma...
Opdivo + Yervoy regimen receives expanded FDA approval
25 January 2016 | By Victoria White
The FDA has approved Opdivo (nivolumab) + Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma...
